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Abstract: Oviductal extracellular vesicles (oEVs) are emerging as key players in the 
gamete/embryo–oviduct interactions that contribute to successful pregnancy. Various positive 
effects of oEVs on gametes and early embryos have been found in vitro. To determine whether these 
effects are associated with changes of embryonic gene expression, the transcriptomes of embryos 
supplemented with bovine fresh (FeEVs) or frozen (FoEVs) oEVs during in vitro culture compared 
to controls without oEVs were analyzed by low-input RNA sequencing. Analysis of RNA-seq data 
revealed 221 differentially expressed genes (DEGs) between FoEV treatment and control, 67 DEGs 
for FeEV and FoEV treatments, and minor differences between FeEV treatment and control (28 
DEGs). An integrative analysis of mRNAs and miRNAs contained in oEVs obtained in a previous 
study with embryonic mRNA alterations pointed to direct effects of oEV cargo on embryos (1) by 
increasing the concentration of delivered transcripts; (2) by translating delivered mRNAs to proteins 
that regulate embryonic gene expression; and (3) by oEV-derived miRNAs which downregulate 
embryonic mRNAs or modify gene expression in other ways. Our study provided the first high-
throughput analysis of the embryonic transcriptome regulated by oEVs, increasing our knowledge 
on the impact of oEVs on the embryo and revealing the oEV RNA components that potentially 
regulate embryonic development. 
Keywords: extracellular vesicles; exosomes; oviduct; embryo; gene expression; EV RNA cargo; EV-
derived mRNAs; EV-derived miRNAs 
 
1. Introduction 
Extracellular vesicles (EVs) are well recognized mediators of cell-to-cell communication [1], a 
function they carry out by transferring their bioactive molecular cargo (RNAs, proteins, lipids, 
metabolites, and genomic DNA) to recipient cells [2,3]. Although at least three different types of EVs 
have been described based on their biogenesis and physical characteristics—exosomes, microvesicles 
and apoptotic vesicles [4]—only the first two types have attracted much attention in recent years, due 
to their contribution to a wide range of physiological and pathological processes such as 
angiogenesis, cell survival, modulation of the immune response, inflammation, and cancer, as well 
as embryonic development [5,6]. In fact, EVs identified in the oviduct and in the uterus have emerged 
as key players in the embryo–maternal dialogue contributing to successful pregnancy [7–9]. 
In particular, the potential role of oviductal EVs (oEVs) has received growing attention in recent 
years, since the oviduct is the place that hosts and supports the first reproductive events [10,11], and 
oEVs could be key modulators of such events. To date, EVs have been identified in the oviduct of 
different species (bovine, mouse, porcine, avian, and turtle) and their functional effects have been 
studied in gametes and embryos (reviewed in Almiñana and Bauersachs [12]). For example, it has 
been shown that oviductal EVs (oEVs) support bovine embryonic development [13,14], canine oocyte 
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maturation [15], modulate sperm capacitation and sperm fertilizing ability in the mouse and in the 
cat [11,16], and regulate polyspermy fertilization in the pig [17]. Regarding the effects of oEVs on 
embryonic development, our laboratory previously demonstrated that oEVs are taken up by the 
bovine embryo during in vitro culture, and that the supplementation of oEVs during in vitro embryo 
culture improved embryonic development and quality in terms of blastocyst rates, cell number, and 
hatching rates [13]. Moreover, we showed that frozen and fresh oEVs had different effects on 
embryonic development and quality [13]. Along the same lines, Lopera-Vásquez [14] reported that 
oEVs enhanced embryo cryosurvival. Furthermore, Lopera-Vásquez [14,18] showed that oEV 
supplementation during in vitro culture altered the expression of a few genes involved in embryonic 
development, metabolism, and epigenetic regulation, making the embryos more similar to their in 
vivo counterparts [14]. These two studies by Lopera-Vásquez et al. [14,18] provided a few hints about 
the potential role of oEVs in modulating embryonic gene expression by using a targeted RT-qPCR 
approach, and called for an in-depth analysis of the impact of oEVs on the embryonic transcriptome. 
Given the wide range of oEV components recently identified in our laboratory (mRNAs, 
proteins, ncRNAs including miRNAs, snoRNAs, snRNAs, and metabolites) [19,20], it is difficult to 
select potential candidates as modulators of embryonic development. To date, only a few miRNAs 
and proteins have been proven to be responsible for oEVs’ functional effects on spermatozoa [11,16], 
while the functional impact of the oEV cargo on embryos and the extent of those effects is not yet 
fully understood. 
Therefore, in the present study we aimed to demonstrate that the RNA cargo in oEVs regulates 
early embryonic development by altering the embryonic transcriptome. We hypothesized that oEVs 
bring RNA components (mRNAs and miRNAs) and proteins into the embryo and thus alter the 
embryonic transcriptome. Moreover, we propose different modes of action by which the RNA cargo 
of oEVs could modify the embryonic transcriptome: (1) oEV-derived mRNAs could be incorporated 
into embryos via EVs and thereby increase the concentration of the delivered transcripts; (2) delivered 
mRNAs could be translated and the corresponding proteins could lead to regulation of embryonic 
gene expression; and (3) oEV-derived miRNAs and other ncRNAs could act by targeting embryonic 
mRNAs, and thus downregulate or modify embryonic gene expression in other ways (e.g., mRNA 
isoform expression, indirect effects on gene expression). In addition, given the differential effect of 
fresh and frozen oEVs on embryonic development, as demonstrated in our previous study [13], we 
also hypothesized that frozen and fresh oEVs affect the embryonic transcriptome differently. To this 
end, we used a low-input RNA-seq approach to profile the transcriptional responses of embryos 
cultured in vitro with fresh and frozen oEVs and controls without the addition of oEVs. Subsequently, 
to unveil the potential oEV RNA components capable of regulating the embryonic development, we 
performed an integrative analysis of mRNA and miRNA cargo identified in oEVs [19] and the 
embryonic transcriptome alterations induced by oEVs. The knowledge derived from our study will 
lead to a more meaningful understanding of the impact of oEVs on the embryo, while revealing the 
oEV RNA cargo potentially involved in the regulation of embryonic development. 
2. Results 
2.1. Oviductal EV Supplementation during In Vitro Embryo Culture Altered the Embryonic Transcriptome 
The oEVs used in this study were derived from cows in the postovulatory stage. In our previous 
studies, characterization of these oEVs revealed a population of small extracellular vesicles (30–100 
nm) resembling exosomes (50%–60% of all vesicles) and a population of larger extracellular vesicles 
(>100 nm) resembling microvesicles (25%–30% 100–150 nm, 10% 150–200 nm) [13,19]. Typical EV 
marker proteins were detected by Western blotting, such as HSP70, ANXA1, MYH9, and HSPA8 
[13,19]. In the present study, we focused on analysis of the transcriptome of embryos cultured in vitro 
with or without oEV supplementation. 
We hypothesized that oEVs bring RNA components (mRNAs and miRNAs) into the embryo, 
which then alter its transcriptome. Moreover, we hypothesized that frozen and fresh oEVs affect the 
embryonic transcriptome differently. To prove our hypothesis, RNA-seq analysis of embryos 
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cultured in vitro with frozen oEVs (FoEVs) and fresh oEVs (FeEVs) and without oEVs (Co, control) 
was performed. Transcripts derived from a total number of 10,832 genes were identified in all 
embryos examined under different in vitro culture (IVC) treatments (after filtering for a minimum 
number of read counts; Supplementary Data S1(Table S1)). To identify genes with altered gene 
expression due to different IVC treatments, statistical analysis was performed between FoEV 
treatment and Co, FeEV treatment and Co, and between both EV treatments (FoEVs and FoEVs). The 
total number of differentially expressed genes (DEGs) for these comparisons was 316, based on a false 
discovery rate (FDR) < 0.05 for the comparison FoEV treatment vs. Co (Supplementary Data S1(Tables 
2–4)). The overlap of DEGs among comparisons is shown in a Venn diagram (Figure 1). 
 
Figure 1. Venn diagrams showing the distribution of differential expressed genes (DEGs) regulated 
by oviductal extracellular vesicle (oEV) treatments. Data were based on a p-value cut-off of 0.001 and 
an FDR of 0.05 (FoEV treatment vs. Co). FoEVs_Co: embryos cultured with frozen oEVs (FoEVs) 
compared to embryos without oEVs (Co, control); FeEVs_Co: embryos cultured with fresh oEVs 
(FeEVs) compared to Co; FoEVs_FeEVs: FoEVs compared to FeEVs. 
Hierarchical cluster analysis of the DEGs obtained for the three comparisons is shown in Figure 
2. The main differences were identified between FoEV treatment and Co (221 DEGs; Figures 1 and 
2A), the lowest for the comparison between FeEV and Co treatments (28 DEGs; Figures 1 and 2B), 
and 67 DEGs for the comparison between EV treatments (Figures 1 and 2C). Furthermore, when an 
additional cut-off was considered (minimum fold change of 1.5), 112, 19, and 46 DEGs were obtained 
for comparisons between FoEV treatment and Co, FeEV treatment and Co, and between EV 
treatments, respectively (Supplementary Data S1(Tables 2–4)). 
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Figure 2. Comparative transcriptome analysis of embryos cultured in vitro under different 
treatments; (A) FoEV-treated and Co embryos; (B) FeEV-treated and Co embryos; (C) FoEV- and 
FeEV-treated embryos (Co: control; FoEV: frozen EV; FeEV: fresh EV). Dendrograms representing 
results of unsupervised hierarchical clustering (HCL) created with Pearson correlation coefficient by 
MeV. Rows show DEGs while columns represent embryo samples collected under different IVC 
treatments. Each sample represents a pool of embryos. Mean-centered expression values (log2 counts 
per million of sample-mean of log2 CPM of all samples) for the samples of the three embryo 
treatments. Color scale is from -2 (blue, lower than mean) to 2 (red, higher than mean). 
Among the 221 DEGs between FoEV-treated and control embryos, 96 were downregulated and 
125 upregulated in FoEV-supplemented embryos compared to control embryos. Of the 125 mRNAs 
upregulated in FoEV-treated embryos compared to control, 20% (25) were annotated as different 
types of small non-coding RNAs (sncRNAs). Among them, 12 were identified as bovine small 
nucleolar RNA, C/D (known as SNORDs, human symbols: SNORD10, SNORD11, SNORD13, 
SNORD15A, SNORD15B, SNORD21, SNORD27, SNORD46, SNORD53B, SNORD70, SNORD103B); 
7 as bovine small nucleolar RNA, H/ACA (known as SNORA, human symbols: SNORA16A, 
SNORA23, SNORA46, SNORA54, SNORA63, SNORA73A, SNHG25), and 6 as small nuclear RNAs 
which play important roles in RNA splicing (human symbols: RNU1-1, RNU1-13P, RNU2-1, RNU4-
2, RNU1-1-like, RNU4-2-like). Among the 28 DEGs in FeEV-treated embryos, 16 were downregulated 
and 12 upregulated upon FeEV treatment compared to control. Finally, among 67 DEGs between 
FoEV- and FeEV-treated embryos, 12 were downregulated and 55 upregulated upon FoEV treatment. 
The complete lists of down- and upregulated genes for each comparison can be found in 
Supplementary Data S1. 
2.2. Functional Annotation Revealed Potential Regulatory Pathways Affected by Oviductal EVs 
To obtain a more meaningful view of how oEVs can modulate the embryo transcriptome, gene 
ontology terms (GO) terms and pathways for DEGs from the three different comparisons (FoEV 
treatment vs. Co; FeEV treatment vs. Co, and FoEV vs. FeEv treatment) were analyzed using 
functional annotation databases in Metascape and with Ingenuity Pathway Analysis (IPA) tools. 
In Figure 3, a Metascape heatmap plot represents the functional enrichment analysis for up- and 
downregulated genes in embryos treated with frozen or fresh EVs compared to control and between 
EV treatments, and shows clusters of enriched functional terms across DEGs from different 
comparisons. The heatmap illustrates that functional terms and pathways related to “embryo 
morphogenesis” were only enriched for genes downregulated in FoEV treatment vs. Co and FeEV 
treatment vs. Co sets. Furthermore, genes downregulated in FoEV treatment vs. Co were also 
enriched for biological processes related to “female gamete generation”, “apoptosis”, “response to 
external stimulus”, “response to osmotic stress”, “telomerase pathway”, “glucose transmembrane 
transport”, and “regulation of lipid metabolic process”. For the upregulated genes in the FoEV 
treatment vs. Co comparison, we found high enrichment of “translation” and also of functional terms 
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involved in “ribosome biogenesis”, “membrane trafficking”, “mitochondrial organization”, and 
“protein methylation”. Additionally, FoEV treatment vs. Co upregulated genes were involved in 
“negative regulation of actin filament polymerization”. When both EV treatments were compared, 
the GO terms found to be enriched were “translation”, “ribonucleoprotein complex biogenesis”, and 
“ribosome biogenesis” for upregulated genes, and “membrane trafficking” for downregulated genes 
in the FoEV treatment vs. FeEV treatment comparison. 
 
Figure 3. Functional enrichment analysis for up- and downregulated genes in embryos treated with 
FoEVs or FeEVs compared to control and between oEV treatments using Metascape tool. Bar graph 
of enriched terms across DEGs colored by p-values representing enriched clusters up to a score of 2. 
More details for the obtained overrepresented functional terms and pathways for each DEG set 
obtained from embryos under different EV treatments compared to control, with highlighted genes 
related to interesting biological processes and pathways can be found summarized in Tables 1–6 and 
in Supplementary Data S2(Tables S1–6). 
Table 1. Metascape functional annotation clusters for downregulated genes in embryos treated with 
FoEVs compared to control. 
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GO:0043065 





GO:0032570 response to progesterone −3.13 3/45 CAV1,FOS,THBS1 
GO:0008630 
intrinsic apoptotic signaling 
pathway in response to 
DNA damage 
−3.12 4/104 EPHA2,MCL1,TRIM32,SIRT1 
GO:0050673 epithelial cell proliferation −2.72 7/446 CAV1,ATF2,EPHA2,THBS1,FRS2,SIRT1,STXBP4 
GO:0048545 response to steroid hormone −2.38 6/385 CAV1,FLT3,FOS,THBS1,SIRT1,CREBRF 
GO:0010035 
response to inorganic 
substance 
−2.17 7/562 CAV1,ATF2,FOS,MEF2A,THBS1,EIF2AK3,SIRT1 
GO:2000147 





GO:0001525 angiogenesis −2.07 7/588 CAV1,ATF2,EPHA2,CCN1,THBS1,EIF2AK3,SIRT1 
R-HSA-
168898 
Toll-like Receptor Cascades  −2.48 4/155 ATF2,FOS,MEF2A,MAP3K1 
M164 
PID ERBB1 DOWNSTREAM 
PATHWAY 








regulation of chromosome 
organization 
−2.61 6/345 TERF1,TTK,TNKS,SIRT1,MIER1,NEK7 
GO:0045786 
negative regulation of cell 
cycle 
−2.42 8/642 APAF1,ATF2,TERF1,THBS1,TTK,TNKS,RYBP,CAB39 
GO:0007051 spindle organization −2.19 4/187 TTK,TNKS,WASHC5,NEK7 
GO:0071897 DNA biosynthetic process −2.09 4/200 TERF1,TNKS,SIRT1,NEK7 










cellular response to external 
stimulus 
−2.65 6/339 FOS,MAP3K1,TNKS,EIF2AK3,SIRT1,SLC38A2 
GO:0009266 
response to temperature 
stimulus 







GO:0007292 female gamete generation −2.69 4/136 TTK,ADAMTS1,WASHC5,SIRT1 
GO:0003006 
developmental process 




hsa04210 Apoptosis −2.66 4/138 APAF1,FOS,MCL1,EIF2AK3,PFKFB3,NANOG 
M255 PID HIF1 TFPATHWAY −2.65 3/66 FOS,MCL1,PFKFB3 
GO:0048598 embryonic morphogenesis −2.66 8/586 
APAF1,EPHA2,ETS2,CCN1,SP3,FRS2,FLRT3,NANO
G 
GO:0007369 gastrulation −2.21 4/185 EPHA2,ETS2,FRS2,NANOG 





−2.50 5/251 SLC20A1,SLC38A2,SLC39A8,SLC5A11,SLC30A7 
GO:0006970 response to osmotic stress −2.35 3/84 ATF2,NFAT5,CAB39 




−2.08 3/105 ADAM10,CDH17,ADAMTS1 
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Table 2. Metascape functional annotation clusters for upregulated genes in embryos treated with 
FoEVs compared to control. 

















metabolism of amino 




R-HSA-72312 rRNA processing −7.31 10/205 
RPL23A,RPL28,RPL39,RPS4X,RPS6,RPS12,RPS17,RP
S21,RPL36,TSR3 









41,MRPS34,  MRPL57,MRPL52 
GO:0072594 
establishment of protein 

























complex I assembly 
−3.62 4/64 NDUFA7,NDUFB7,NDUFA13,NDUFB11 
































protein methylation −4.03 3/19 ETFB,METTL22,EEF2KMT 





−2.29 4/146 AP2M1,AP2S1,VAMP8,HIP1R 
GO:0002478 




−2.02 4/175 AP2M1,AP2S1,PSMD4,VAMP8 








GO:0042254 ribosome biogenesis −3.28 7/297 RMRP,RPL23A,RPS6,RPS17,RPS21,TSR3,NUDT16 






programmed cell death 
−2.50 3/62 SPG7,YWHAH,HIP1R 
GO:1905710 
positive regulation of 
membrane permeability 








regulation of epidermal 
growth factor receptor 
signaling pathway 
−3.13 4/86 HIP1R,NUP62,RNF126,MVB12A 
GO:0038127 ERBB signaling pathway −2.32 4/143 HIP1R,NUP62,RNF126,MVB12A 
GO:0030837 
negative regulation of 
actin filament 
polymerization 
−2.58 3/58 CAPG,TMSB4X,HIP1R,CHMP2A 
GO:0051494 
negative regulation of 
cytoskeleton 
organization 
−2.27 4/148 CAPG,TMSB4X,HIP1R,CHMP2A 
R-HSA-
8953897 


















−2.01 4/176 PSMD4,SEM1,NUP62,SLC39A4 
Table 3. Metascape functional annotation clusters for downregulated genes in embryos treated with 
FeEVs compared to control. 




−4.23 3/146 FLT3,FOS,GPR83,CTSL 
GO:0048545 
response to steroid 
hormone 
−2.99 3/385 FLT3,FOS,GPR83 
GO:0032870 
cellular response to 
hormone stimulus 
−2.25 3/703 CTSL,FLT3,FOS 
GO:0002521 leukocyte differentiation −3.90 4/516 EPHA2,FLT3,FOS,DNAJB9 
GO:0070848 
response to growth 
factor 
−3.30 4/739 EPHA2,FLT3,FOS,CCN1,ZNF568 
GO:0070372 
regulation of ERK1 and 
ERK2 cascade 












−2.38 3/629 EPHA2,CCN1,ZNF568 




ending in birth or egg 
hatching 
−2.35 3/646 EPHA2,CCN1,ZNF568 
GO:0071363 
cellular response to 
growth factor stimulus 
−2.24 3/709 FLT3,FOS,CCN1 
GO:0043408 
regulation of MAPK 
cascade 
−2.13 3/774 EPHA2,FLT3,CCN1 
Table 4. Metascape functional annotation clusters for upregulated genes in embryos treated with 
FeEVs compared to control. 
GO Term Description Genes 
GO:0006357  regulation of transcription by RNA polymerase II ZNF532, ZFP1, ZNF709 
GO:0006366  transcription by RNA polymerase II ZNF532, ZFP1, ZNF709 
GO:0006355  regulation of transcription, DNA-templated ZNF532, ZFP1, ZNF709 
GO:0051573  negative regulation of histone H3-K9 methylation DNMT3B 
GO:0090116  C-5 methylation of cytosine DNMT3B 
GO:0051571  positive regulation of histone H3-K4 methylation DNMT3B 
GO:0006853  carnitine shuttle CPT1A 
GO:0032000  positive regulation of fatty acid beta-oxidation CPT1A 
GO:1902001  fatty acid transmembrane transport CPT1A 
GO:0070981 L-asparagine biosynthetic process ASNS 
GO:0006529  asparagine biosynthetic process ASNS 
GO:0070453 regulation of heme biosynthetic process SRRD 
GO:1901463  regulation of tetrapyrrole biosynthetic process SRRD 
GO:1901401  regulation of tetrapyrrole metabolic process SRRD 
GO:1901647  positive regulation of synoviocyte proliferation NEAT1 
GO:1901645 regulation of synoviocyte proliferation NEAT1 
GO:0002941  synoviocyte proliferation NEAT1 
GO:0051058  
negative regulation of small GTPase mediated signal 
transduction 
CGNL1 
GO:0051056  regulation of small GTPase mediated signal transduction CGNL1 
GO:0007015 actin filament organization CGNL1 
GO:0006614  SRP-dependent cotranslational protein targeting to membrane RPL23A 
GO:0006613  cotranslational protein targeting to membrane RPL23A 
GO:0000184  
nuclear-transcribed mRNA catabolic process, nonsense-
mediated decay 
RPL23A 
Table 5. Metascape functional annotation clusters for downregulated genes in embryos treated with 
FoEVs compared to FeEVs. 
GO Term Description LogP In Term/In List Genes 
R-HSA-199991 membrane trafficking −2.48 3/634 PAFAH1B2,DENND4C,SBF2 
R-HSA-5653656 vesicle-mediated transport −2.41 3/673 PAFAH1B2,DENND4C,SBF2 
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Table 6. Metascape functional annotation clusters for upregulated genes in embryos treated with 
FoEVs compared to FeEVs. 
GO Term Description LogP In Term/In List Genes 





major pathway of rRNA 
processing in the nucleolus 
and cytosol 
−4.49 5/185 RPL39,RPS4X,RPS6,RPS12,DDX49 
R-HSA-72312 rRNA processing −4.27 5/205 RPL39,RPS4X,RPS6,RPS12,DDX49 
GO:0006614 
SRP-dependent cotranslational 
protein targeting to membrane 




−4.09 4/115 RPL39,RPS4X,RPS6,RPS12 
GO:0045047 protein targeting to ER −4.05 4/118 RPL39,RPS4X,RPS6,RPS12 





−4.02 4/120 RPL39,RPS4X,RPS6,RPS12 
GO:0072599 
establishment of protein 
localization to endoplasmic 
reticulum 
−3.99 4/122 RPL39,RPS4X,RPS6,RPS12 
GO:0070972 
protein localization to 
endoplasmic reticulum 
−3.68 4/147 RPL39,RPS4X,RPS6,RPS12 
R-HSA-72649 
translation initiation complex 
formation 
−3.68 3/58 RPS4X,RPS6,RPS12 
R-HSA-72702 
ribosomal scanning and start 
codon recognition 
−3.68 3/58 RPS4X,RPS6,RPS12 
R-HSA-72766 translation −3.56 5/291 RPL39,RPS4X,RPS6,RPS12,MRPL36 
GO:0006413 translational initiation −3.23 4/193 RPL39,RPS4X,RPS6,RPS12 




−3.10 4/209 RPL39,RPS4X,RPS6,RPS12 
GO:0090150 
establishment of protein 
localization to membrane 
−2.36 4/334 RPL39,RPS4X,RPS6,RPS12 
R-HSA-71291 
metabolism of amino acids 
and derivatives 
−2.20 4/372 RPL39,RPS4X,RPS6,RPS12 







GO:0042254 ribosome biogenesis −2.55 4/297 RMRP,RPS6,DDX49,MRPL36 
The analysis of the DEG lists performed with IPA software (gene expression core analysis) 
revealed basically similar results, i.e., similar overrepresented functional terms and pathways as were 
obtained with Metascape. Thus, the analysis was focused on genes related to embryonic development 
by searching for all enriched related functions and generating a network of the associated genes, 
including 17 miRNAs potentially targeting the genes in the network and previously identified in 
bovine oEVs [19] (Figure 4; Supplementary Data S2(Tables S9–10)). Overall, the majority of the 
assigned genes had lower mRNA levels in the embryos supplemented with frozen oEVs. The genes 
with the highest connectivity were Nanog homeobox (NANOG), MCL1 apoptosis regulator, BCL2 
family member (MCL1), Fos proto-oncogene, AP-1 transcription factor subunit (FOS), activating 
transcription factor 2 (ATF2), apoptotic peptidase activating factor 1 (APAF1), cytochrome c, somatic 
(CYCS), and thrombospondin 1 (THBS1). The processes with the highest connectivity were 
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“apoptosis of embryonic cell lines”, “proliferation of embryonic cells”, and “cell viability of 
embryonic cell lines”. The genes targeted by the highest number of miRNAs were APAF1 (five 
miRNAs), FOS (three miRNAs), THBS1 (three miRNAs), and RING1 and YY1 binding protein (RYBP, 
three miRNAs). 
 
Figure 4. Network of FoEVs vs. Co DEGs involved in embryonic development. A network of 
overrepresented biological functions related to embryonic development and their assigned FoEV-
treated embryos vs. control DEGs was generated using ingenuity pathway analysis software. 
MicroRNAs revealed by the software to be potential upstream regulators were added to the network 
(restricted to miRNAs known to be present in bovine oEVs) as well as further connected DEGs. Genes 
are colored by log2 fold change ratio, blue for downregulated and red for upregulated genes. 
2.3. Comparative and Integrative Analysis of Embryonic mRNAs Altered under oEV Treatment and oEV-
Derived mRNAs. 
To unveil the oEV mRNA cargo responsible for the embryonic transcriptomic changes observed 
in the present study, we compared the mRNAs identified in oEVs in our previous study [19] at the 
post-ovulatory stage (S1) and the embryonic mRNAs identified under oEV treatments (from the post-
ovulatory stage in FoEV-treated embryos) from the present study. The Venn diagram in Figure 5A 
shows a comparison of all detectable genes in the embryos (Supplementary Data S1(Table S1)), the 
DEGs for the comparison FoEV treatment vs. Co (Supplementary Data S1(Table S2)), all detectable 
genes in the postovulatory-stage oEVs (Supplementary Data S1(Table S7)), and the top 500 genes 
with highest expression in postovulatory-stage oEVs (based on transcripts per million, TPM; 
Supplementary Data S1(Table S8)). The comparison of all detectable genes revealed an overlap of 
9404 genes. Considering that the transcripts with low concentrations in oEVs might not be very likely 
to have an effect on the embryo, we selected the top 500 most abundant transcripts that showed a 
frequency of more than 25 TPM [19], resulting in 453 embryonic mRNAs in total and 14 of the DEGs 
of the FoEV treatment vs. Co comparison (Supplementary Data S1(Table S9)) as being in common 
with the top 500 mRNAs in oEVs. 
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To further test the first of our hypotheses, that a part of the alterations of the embryonic 
transcriptome could be directly due to RNAs derived from oEVs that simply increase the number of 
these transcripts in the embryo due to oEV delivery, we compared upregulated DEGs in frozen-EV-
derived embryos compared to control (125 genes, Supplementary Data S1(Table S5)) to all mRNAs 
in oEVs and the top 500 most abundant mRNAs in oEVs (Figure 5B). This comparison revealed 86 
upregulated genes in common with all oEV mRNAs (Supplementary Data S1(Table S9)) and 14 
upregulated genes in common with the top 500 most abundant mRNAs in oEVs (Supplementary 
Data S1(Table S9)). In contrast, the genes downregulated in frozen-EV-supplemented embryos (96 
genes, Supplementary Data S1(Table S6)) did not overlap with the top 500 most abundant mRNAs in 
oEVs (Figure 5C), whereas a list of 87 genes in common with all mRNAs in oEVs was obtained 
(Supplementary Data S1(Table S9)). 
 
Figure 5. Comparative analysis of embryonic mRNAs altered under oEV treatment and oEV-derived 
mRNAs and ncRNAs. (A) Venn diagrams representing the comparison among all identified mRNAs 
in embryos, upregulated DEGs in embryos supplemented with frozen EVs (FoEVs) compared to 
control embryos, all mRNAs in oviductal EVs (oEVs), and top 500 most abundant mRNAs in oEVs; 
(B) comparison among upregulated DEGs in FoEV treatment vs. Co, all mRNAs in oEVs, and the top 
500 most abundant mRNAs in oEVs; (C) comparison among downregulated DEGs in DEGs in FoEV-
treated vs. Co embryos, all mRNAs in oEVs, and the top 500 most abundant mRNAs in oEVs; (D) 
gene set enrichment analysis (GSEA) showing enrichment of the top 500 most abundant mRNAs in 
oEVs in the rank list of all genes detectable in embryos supplemented with frozen oviductal EVs 
(oEVs) ranked by differential expression (red = higher expression in FoEVs-treated embryos 
compared to control embryos, blue = lower expression), and the 19 genes with the highest enrichment 
scores; (E) GSEA enrichment plot showing enrichment of oEVs-derived non-coding RNAs (ncRNAs) 
in the rank list (same list as in D), and the 10 ncRNAs with the highest enrichment scores. 
Furthermore, we used gene set enrichment analysis (GSEA) [21] to identify significantly 
enriched genes in embryos which might be derived from oEVs by comparison to (1) the top 500 genes 
with the highest expression in oEVs and (2) non-coding RNAs contained in oEVs (Supplementary 
Int. J. Mol. Sci. 2020, 21, 1303 13 of 28 
 
Data S1(Table S10)) [19]. The GSEA plot in Figure 5D shows a substantial enrichment of the top 500 
most abundant mRNAs identified in oEVs towards the upregulated genes in oEV-supplemented 
embryos. The list of the 19 genes with the highest enrichment scores obtained from this analysis is 
also shown in Figure 5D. Moreover, a strong enrichment was also found for a group of ncRNAs 
identified in oEVs containing mainly small nucleolar RNAs (snoRNAs) and spliceosomal RNAs, as 
illustrated in Figure 5E. The complete lists of GSEA results can be found in the Supplementary Data 
S1(Tables S11 and S12). Comparison of Venn diagram and GSEA results revealed a set of 14 genes 
common to both analyses as potential mRNAs contained in oEVs contributing to upregulation of 
embryonic gene expression, as well as a set of small non-coding RNAs, including snoRNAs and 
spliceosomal RNAs. 
Moreover, transcripts delivered by oEVs to the embryo could be translated and regulate gene 
expression in the embryo. To identify potential factors upregulating embryonic gene expression, the 
upregulated genes in FoEV-treated embryos were subjected to transcription factor (TF) analysis using 
ChIP-X Enrichment Analysis Version 3 (ChEA3) [22]. This analysis revealed five factors, HMGN3, 
JUND, NME2, PIN1, and YBX1, of which the mRNAs were contained in the top 500 most highly 
abundant mRNAs in oEVs, potentially regulating 53 of the upregulated genes (Supplementary Data 
S1(Table S13)). 
2.4. Comparative Analysis of Embryonic mRNAs Altered under oEV Treatment and Potential Genes 
Targeted by oEV-Derived miRNAs 
To test the second of our hypotheses, that the alterations of the embryonic transcriptome could 
also be due to miRNAs contained in oEVs that downregulate mRNAs in the embryo, we used three 
different approaches. 
The first approach was based on identifying potential miRNAs that could target the identified 
downregulated genes in embryos treated with oEVs and comparing them to identified miRNAs in 
oEVs. Figure 6A represents the comparison of potential miRNAs targeting identified downregulated 
genes in embryos using miTarBase and TargetScan databases to the miRNAs identified in oEVs (62 
miRNAs, Supplementary Data S1(Table S14)). Based on the overlapping miRNAs, potential target 
genes derived from miTarBase and TargetScan datasets were compared to identified downregulated 
genes in embryos (Figure 6B, Supplementary Data S1(Table S14)). This first approach provided a list 
of 75 predicted target mRNAs of miRNAs contained in oEVs common to genes downregulated in 
embryos supplemented with FoEVs. 
The second approach was based on identifying potential target genes of the miRNAs identified 
in oEVs and comparing them to the observed downregulated genes in embryos treated with oEVs. 
The Venn diagram illustrated in Figure 6C shows the results of this comparison, representing 
potential target genes derived from miTarBase and TargetScan databases and the downregulated 
genes identified in embryos (Supplementary Data S1(Table S14)). This second approach provided a 
list of 63 predicted targets of miRNAs in oEVs and common to downregulated genes in embryos 
supplemented with FoEVs. A comparison of the lists of target genes derived from the two approaches 
provided a list of 57 commonly identified genes, of which expression is probably downregulated in 
frozen-oEV-supplemented embryos due to miRNAs derived from oEVs (Figure 6D, Supplementary 
Data S1(Table S14)). 
Since we found genes downregulated in frozen-oEV-supplemented embryos to be mainly 
associated with functions such as embryonic development, embryo death, embryonic pluripotent cell 
lines etc. in the IPA analysis (Figure 4), we looked for potential activated upstream regulators and 
selected significant miRNAs that were then added to the network. Seventeen miRNAs identified in 
oEVs were connected to potential targets in the network according to the IPA knowledge base. Fifteen 
of these miRNAs were also contained in the 62 miRNAs potentially targeting identified 
downregulated genes in embryos using the miTarBase and TargetScan databases (Figure 6A). 
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Figure 6. Identification of potential miRNAs in oviductal EVs responsible for downregulation of 
embryo gene expression using two different approaches: (1) From identified downregulated genes in 
embryos to potential miRNAs in oEVs and (2) From identified miRNAs in oEVs to potential target 
genes in embryos. (A) Venn diagram representing the comparison among potential miRNAs targeting 
identified downregulated genes in embryos using miTarBase and TargetScan databases and 
identified miRNAs in oEVs; (B) Venn diagram representing the comparison of potential target genes 
of the miRNAs derived from the previous comparison and identified downregulated genes in 
embryos; (C) Venn diagram representing the comparison among potential target genes derived from 
identified miRNAs in oEVs using miTarBase and TargetScan databases and identified downregulated 
genes in embryos; (D) comparison of lists of target genes from both approaches. 
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2.5. Integrative Analysis of mRNAs and miRNAs Contained in oEVs and Embryonic Transcriptome 
Alterations Induced by oEVs 
Datasets of oEV mRNAs (top 500) and predicted targets of oEV miRNA cargo as well as DEGs 
in embryos in response to FoEVs were plotted in a circular layout (Figure 7 and Supplementary Data 
S1(Table S15)), providing an integrative view of embryonic gene expression data and RNAs derived 
from oEVs and their potential effects on embryonic gene expression. Figure 7 shows the overlaps 
among gene lists at the gene level. This meta-enrichment summary analysis illustrated the two 
hypotheses postulated in the present study: (1) mRNAs derived from oEVs increase concentrations 
of a proportion of mRNAs in embryos treated with oEVs, which was supported by the fact that a 
considerable proportion of DEGs that were upregulated in embryos supplemented with frozen oEVs 
were present in the top 500 mRNAs in oEVs, and no overlap was found with genes downregulated 
in supplemented embryos; and (2) miRNAs derived from oEVs downregulate mRNAs in embryos 
treated with oEVs, which was supported by the overlap of the genes downregulated in embryos 
supplemented with frozen oEVs (DW_FoEVsEmb) and the genes predicted as targets of oEV miRNAs 
(PG_miRNA_EVs_T1 and PG_miRNA_EVs_T2). 
 
Figure 7. Meta-enrichment analysis summary for list of identified and potential target genes in 
embryos regulated by miRNAs in oEVs. Input lists: (1) the top 500 mRNAs in oEVs (Top500_EVs, 
Purple); (2) the upregulated genes in FoEV-treated versus Co embryos (UP_FoEVsEmb, Orange); (3) 
the downregulated genes in FoEV-treated versus Co embryos (DW_FoEVsEmb, Red); (4) the potential 
genes targeted by miRNAs contained in oEVs based on Approach 1 from identified downregulated 
genes (PG_miRNAs_Evs_T1, Blue); and (5) based on Approach 2 from identified miRNAs in oEVs 
(PG_miRNAs_Evs_T2, Green). Circular plot representing overlaps among gene lists at the gene level, 
where purple lines link identical genes and blue lines link genes belonging to the same enriched 
ontology term. The inner circle represents gene lists, where hits are arranged along the arc. Genes hit 
multiple lists are colored in dark orange, and genes unique to a list are shown in light orange. 
Further functional annotation analysis of this integrative data was represented in a heatmap of 
enriched terms across input gene lists (Figure 8A, Supplementary Data S2(Tables S7 and S8)). 
Interestingly, functional terms related to “mitochondria organization”, “ribosome biogenesis”, 
“ribonucleoprotein complex biogenesis”, “cellular response to external stimuli”, “SRP-dependent co-
translational protein targeting to membrane”, “protein methylation”, and “vesicle-mediated 
transport” were highly enriched for the upregulated genes in embryos supplemented with frozen 
oEVs and the top 500 oEV mRNA datasets, while functional terms involved in “response to inorganic 
substances”, “cellular protein catabolic process”, “response to endoplasmic reticulum stress”, 
“regulation of intrinsic apoptosis signaling pathways”, and “positive regulation of apoptotic process” 
Int. J. Mol. Sci. 2020, 21, 1303 16 of 28 
 
were highly enriched in downregulated genes (frozen oEV embryo treatment), predicted target genes 
derived for miRNAs in oEVs, and the top 500 oEV mRNA datasets. Interestingly, functional terms 
related to “reproductive structure development” were highly enriched in downregulated genes 
(frozen oEV embryo treatment), predicted target genes derived for miRNAs in oEVs, and the top 500 
oEV mRNA datasets. Figure 8B provides a Metascape network of these enriched terms and the 
protein–protein interaction enrichment analysis. 
 
Figure 8. (A) Metascape heatmap of enriched terms across input gene lists representing the top 100 
functional clusters: (1) the top 500 mRNAs in oEVs, (2) the upregulated genes in FoEV treatment vs. 
Co, (3) the downregulated genes in FoEV-treated vs. Co embryos, (4) the potential genes targeted by 
miRNAs in oEVs based on Approach 1 from the identified downregulated genes, and (5) based on 
Approach 2 from identified miRNAs in oEVs, all colored by p-values. (B) Metascape network of 
enriched terms and protein–protein interaction enrichment analysis of the same input lists. 
Pathway/cluster IDs shared across multiple lists have the same colors and nodes sharing the same 
cluster ID are closer to one another. 
3. Discussion 
This study demonstrated that the supplementation of IVC media with oEVs alters the embryonic 
transcriptome. Moreover, differences in embryonic gene expression were found between embryos 
supplemented with oEVs that were frozen before adding to IVC (FoEVs) and with fresh oEVs 
(FeEVs). In the following sections, we discuss these different effects of FoEVs and FeEVs on the 
embryo transcriptome, which supported the differential functional changes observed in embryonic 
development when FeEVs and FoEVs were used in a previous study [13]. Moreover, we discuss 
different modes of action through which the oEV RNA cargo could regulate the embryo 
transcriptome and embryonic development by providing different modes of integrative analysis of 
data derived from our studies.  
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3.1. Differential Effect of Fresh and Frozen oEVs on Embryonic Transcriptome 
The differential functional effects of fresh and frozen oEVs on in vitro embryonic development, 
as demonstrated in on our previous study [13], were reflected in the observed changes in the 
embryonic transcriptome in the present study. It is worth mentioning here that both oEV treatments 
were obtained from the same oviducts and split into two samples for FoEV and FeEV treatments. 
Thus, the only difference in the oEVs used for IVC supplementation was the freeze–thaw step for the 
FoEV samples. Studies on the effect of storage of EVs at −80 °C have shown controversial results. 
While some studies have indicated that storing EV samples at −80 °C does not alter EV morphology 
or size [23,24], others have demonstrated that EV integrity can be disrupted by freezing–thawing 
[25,26]. Boch and colleagues [25] evaluated the impact of one and four freeze–thaw steps on EV 
damage and showed that no measurable differences in the particle size distribution and concentration 
measured by nanoparticle tracking analysis (NTA) were observed after the first freeze–thaw step. 
However, four freeze–thaw cycles induced a slight increase in the particle size distribution and 
particle number for EVs stored in PBS in contrast to EVs stored in Trehalose, a protein stabilizer and 
cryoprotectant widely used in the food and pharmaceutical industries. We hypothesized that freezing 
might induce membrane alterations in FoEVs and faster leaking or release of EV content compared 
to FeEVs, thus resulting in a better transfer of the cargo to target cells. The study by Teng et al. (2015) 
[27] supported our hypothesis, showing a significant reduction in the bi-layer membrane of frozen 
vesicles (−80 °C) when compared to fresh EVs, even when only imperceptible changes of size and 
concentration were observed in EVs after one step of freezing–thawing [25]. Moreover, Maroto et al. 
(2016) [26] showed that in exosome preparations stored at −80 °C, proteins appeared in the 
supernatant fraction, suggesting that distinct protein groups leak from exosomes even at a −80 °C 
storage temperature. On the other hand, studies on EV cargo have shown that freezing seems to 
almost completely preserve the EV-associated proteins [28] and does not impair their functionality 
[23,29], as we observed in our study. It is worth noting that most EV functional studies have been 
based on frozen EVs for practical reasons, or due to the impossibility of performing functional studies 
immediately after EV isolation and characterization. However, not many studies have compared the 
functional effects of frozen and fresh EVs on cells to date. Further studies are required to elucidate 
the impact of the freezing process on EVs’ integrity, cargo, and functional effects, and the use of 
protective substances such as Trehalose. Nevertheless, the results from our laboratory provide clear 
evidence of the positive effect of fresh and frozen oEVs on embryonic development [13], and the 
extent of such effects to inducing modifications in embryonic development. 
3.2. Oviductal EVs Regulate Early Embryonic Development by Altering the Embryonic Transcriptome 
To date, our study represents the first high-throughput analysis of the effects of oEVs on the 
embryonic transcriptome. Two previous studies using a targeted approach by RT-qPCR showed that 
in vitro oEV supplementation induced few changes in gene expression related to epigenetic 
alterations, metabolism, and embryonic development [14,18]. Five genes, PAG1, AQP3, LDLR, 
DNMT3A, and SNRPN, were found to be upregulated in embryos when oEVs or isthmus-derived 
oEVs were used in in vitro embryo culture compared to control (with serum without EV depletion), 
while only two genes, interferon tau (IFNT) and PLAC8, were found to be downregulated in embryos 
compared to control (in absence of serum). Interestingly, a few genes have been studied in embryos 
cultured in media different to the common SOF media used in bovine embryo culture [30] (TCM199 
versus DMEM), showing that the effect of oEVs on embryonic gene expression of CX43/GJA1, 
GAPDH, and G6PD9 also depends on the medium used. However, all of the 10 genes altered due to 
oEV treatments in Lopera-Vasquez et al. [14,18] were found among the DEG sets in our study, which 
could be explained by different reasons: different oEV sources (in vitro versus in vivo origin), 
oviducts related to the side of ovulation and stage of the estrous cycle (ipsi- or/and contralateral 
oviducts; mid-luteal phase versus post-ovulatory), anatomical region of the oviduct (isthmus and 
ampulla versus complete oviductal fluid), EV isolation method, concentration of oEV vesicles used, 
the medium used for embryo culture in which the oEVs were diluted and the use of serum (without 
EV depletion vs. with depletion) as a supplement, and the methodology used for analyzing gene 
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expression (RT-qPCR vs. low-input RNA-seq). The current knowledge about the effect of oEVs on 
embryonic development and the differences found among studies emphasizes the need for further 
studies to examine different variables that could affect the embryo oEV treatment (e.g., medium of 
embryo culture, supplements, duration of co-incubation, EV source, isolation method, and 
concentration) in order to establish reliable protocols that can be used to optimize in vitro embryo 
production in different species. 
On the other hand, da Silveira et al. [31] analyzed the effect of EVs from follicular fluid during 
in vitro maturation and in vitro embryo culture on embryonic development and embryonic gene 
expression, and showed that genes involved in embryonic development (ACSL6, CDH1, REST) or 
methylation (DNMT3A) were altered due to follicular EV treatment during IVC. Although CDH1, 
REST, and DNMT3A have been identified in oEVs (not ACSL6), expression of any of these genes was 
altered in our study. It is worth noting that da Silveira et al. [31] found differences in embryonic gene 
expression between embryos supplemented with EVs from pre-ovulatory follicles and control for 
ACSL6, between treatment with EVs from follicles 3–6 mm in diameter and control for CDH1, and 
between both EV treatments and control for REST, indicating an important effect of the source of the 
EVs. The data derived from this study indicated the importance of the EV source for follicular or 
oviductal EVs. 
In our study, we found that 25 of the 125 mRNAs upregulated in FoEV embryos compared to 
controls were annotated as different types of small non-coding RNAs (sncRNAs), such as small 
nucleolar RNA, C/D (known as SNORDs), small nucleolar RNA, H/ACA (known as SNORA), and 
six small nuclear RNAs, which play important roles in RNA splicing. To date, with the exception of 
the studies addressing the regulatory function of miRNAs in embryonic development [32,33], the 
regulatory function of other classes of sncRNAs in the embryo remains largely unknown. Small 
nucleolar RNAs form a specific class of small (60–170 nucleotides) non-coding RNAs that is best 
known for guiding the post-transcriptional modification of other non-coding RNAs such as 
ribosomal RNAs (rRNAs) and small nuclear RNAs (snRNAs) [34,35]. Additionally, snoRNAs have 
key regulatory functions in various other cellular processes, and their altered expression has been 
associated with a wide range of disorders; they have been suggested as useful diagnostic tools and 
biomarkers in endometrial and lung cancers [36,37]. El Hajj et al. [38] suggested that decreased 
SNORDs promoter region methylation in ICSI children may modulate cancer susceptibility, based 
on the identification of SNORDs such as SNORD11 as being differentially methylated in ICSI versus 
control umbilical cord blood samples, showing a relationship to processes during early embryonic 
development. Interestingly, several SNORDs have been identified in EVs secreted by embryos during 
in vitro culture [39]. From a total of 32 snoRNAs identified, two (SNORD110, SNORD81) were 
exclusively present in media from viable embryos, whereas media from non-viable embryos had 
three exclusive snoRNAs (SCARNA24, SNORD97, SNORD48), indicating them as potential 
biomarkers of embryo viability. However, none of these snoRNAs were found in oEVs or found to 
be altered in the embryonic transcriptome due to oEV treatment. By contrast, the small nucleolar 
RNA host gene 3 (Snhg3), identified in oEVs, has been shown to be essential for self-renewal and 
pluripotency maintenance of murine embryonic stem cells (mESCs), and knockdown of Snhg3 
disrupted mouse early embryonic development [40]. Furthermore, this study showed that Snhg3 
formed a positive feedback network with Nanog and Oct4 and interacted with 126 proteins in mESCs. 
Interestingly, the bovine SNHG3 gene hosts the snoRNA genes LOC112443630, LOC112443631, and 
LOC112443632, belonging to the snoRNA SNORA73 family, of which LOC112443631 was found to be 
upregulated in FoEV-treated embryos. Another very recent study analyzed sncRNA expression in 
bovine IVF embryos during the maternal-to-zygotic transition (MZT) period and found a marked 
increase of sncRNAs, including snoRNAs, during the time of embryonic genome activation [41]. 
Based on the obtained results, the authors suggested a possible regulatory role of snoRNAs during 
the MZT in mammalian embryogenesis [41]. Although the role of snoRNAs in embryonic 
development is not very clear, the results of our and other studies call for further investigation. 
To conclude this section, we would like to mention that the observed changes in embryonic gene 
expression as a result of embryo treatment with oEVs were analyzed after 8 days of IVC with oEVs. 
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We hypothesize that greater transcriptome changes in embryos treated with oEVs could be found if 
embryos were analyzed after a shorter period of IVC, for example after a few hours. Bland et al. [42] 
observed changes in the T-cell transcriptome after as little as 0.5 h of exosome treatment, while other 
transcriptome changes were observed after 8h of treatment. This study suggested that exosome 
treatment elicits a dynamic transcriptomic signature in cytotoxic T cells that becomes apparent for 
some clusters of genes at 0.5 h, while others needed a longer treatment period. Therefore, it is likely 
that a dynamic transcriptome response to oEV treatment might also be observed in embryos at 
different culture time points, and also depending on the embryo stage. 
3.3. Regulation of the Embryonic Transcriptome by oEV-Derived mRNAs: mRNAs in oEVs Upregulate 
mRNAs in oEV-Treated Embryos 
In our study, 125 genes were upregulated in embryos upon FoEV treatment during IVC. We 
hypothesize that this upregulation could be in part due to the incorporation of transcripts delivered 
by the oEVs to the embryo after uptake. An example of this oEV control of gene expression could be 
the higher gene expression of SPINT2 found in FoEV-treated embryos compared to controls, and its 
presence in the top 500 most abundant transcripts identified in oEVs. Moreover, the functional 
analysis revealed that SPINT2 is associated with “epithelial cell morphogenesis involved in placental 
branching” and “epithelial cell differentiation involved in embryonic placenta development”. 
Moreover, it has been shown that in mice, Spint2 contributes to the appropriate development of the 
embryo, as indicated by Spint2 knockout embryos showing clefting of the embryonic ectoderm, 
neural tube defects, and defective placental branching morphogenesis [43]. 
Furthermore, once the transcripts have been incorporated into the embryos, they could be 
translated into proteins that could regulate embryonic gene expression of the embryos, such as 
transcription factors. Interestingly, for one of the predicted regulators of a proportion of the FoEV-
treated embryo upregulated genes, Y-box binding protein 1 (YBX1), the mRNA and the protein were 
both contained in the oEVs. YBX1 is a multifunctional protein, regulating cellular processes as a TF, 
involved in regulation of apoptosis, translation, cell proliferation, mRNA splicing, repair, 
differentiation, and stress response, and is also found in extracellular vesicles [44,45]. Recently, YBX1 
has been identified as being involved in small ncRNA and mRNA sorting into exosomes [46,47]. 
Regarding a potential function in embryonic development, Ybx1 has been shown to play essential 
roles in maternal mRNA stability and early embryogenesis of zebrafish during the maternal-to-
zygotic transition [48]. Additionally, PRDX2 and NEAT1, genes of which the expression was also 
upregulated in embryos under FoEV treatment and which are targeted by transcription factor JUND, 
also identified in oEVs, play an important role during embryonic development. Higher expression of 
PRDX2 has been associated with a greater viability of oocytes and embryos [49,50]. Moreover, a 
significantly lower expression of PRDX2 was found in the first-trimester villous cytotrophoblasts of 
patients with recurrent miscarriage compared to healthy controls. The knockdown of PRDX2 
inhibited proliferation and increased apoptosis of trophoblast cells [51], while the lncRNA Neat1 has 
been found to play a key role in corpus luteum formation and the establishment of pregnancy in a 
subpopulation of mice [52]. On the other hand, PSMD4 (also known as Rpn10) was also upregulated 
in embryos under FoEV treatment and potentially regulated by PIN1; it has been shown to be 
essential for mouse development, since Rpn10 knockout resulted in early embryonic lethality [53]. 
Moreover, PSMD4 protein seems to be involved in sperm–oocyte binding ability in pigs [54]. 
3.4. Regulation of the Embryonic Transcriptome by oEV-Derived miRNAs: miRNAs in oEVs Downregulate 
mRNAs in the Embryo 
Our data analysis predicted that 62 miRNAs present in oEVs could target 57 out of the 96 
obtained downregulated genes in embryos under FoEV treatment compared to control. Interestingly, 
some of these genes are involved in reproductive structure development processes. For example, Sp3 
transcription factor (SP3) is involved in “trophectodermal cell differentiation” and “embryonic 
process involved in female pregnancy”, and can be targeted by four miRNAs identified in oEVs: miR-
27a-3p, miR-484, miR-1260b, and miR-218-5p. Sp3 transcription factor is ubiquitously expressed in 
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early embryos and, as an Sp1-like transcription factor, is a regulator of embryonic development in 
vertebrates [55]. Moreover, Sp3-/- mutant mice showed growth retardation and died at birth [56]. 
Another example is the gene NANOG, which is associated with “functional embryonic 
morphogenesis”, “embryonic morphogenesis”, and “gastrulation” and can be targeted by seven 
different miRNAs present in oEVs: miR-34a-5p, miR-34c-5p, miR-34b-3p, miR-335-5p, miR-128-3p, 
miR-150-5p, and miR-125b-2-3p. These two examples, among others discussed in the next section, 
revealed how oEV-derived miRNAs can modulate embryonic gene expression by downregulating 
mRNAs in the embryo. 
Among the 96 genes downregulated in embryos treated with FoEVs, we found different 
molecules involved in toll-like receptor (TLR) pathways (TLR 2-10 pathways), as shown by the 
Metascape functional analysis. The TLRs are a family of innate immune system receptors which 
recognize various molecular patterns of microbial pathogens, inducing antimicrobial immune 
responses [57], and also have an important role at the maternal–fetal interface [58]. It has been 
proposed that exosomal miRNAs such as let-7, miR-21, and miR-29a, identified in oEVs, can act as 
an unconventional mode to activate TLR7 in mice and cause neurodegeneration and tumor growth 
and metastasis [59,60]. In the same line, milk exosomal miRNAs have been shown to decrease LPS-
induced TLR4/NF-κB signaling pathway activation, reducing LPS-induced inflammation through the 
NF-κB pathway and inhibiting LPS-induced apoptosis via the p53 pathway [61]. Altogether, these 
data suggest that miRNAs present in oEVs could regulate components of TLR pathways in the 
embryo, modulating the maternal immune system at the maternal–fetal interface. 
3.5. Unveiling the Potential of oEV RNA Components to Regulate Embryonic Development 
To unveil the potential of oEV RNA components to regulate embryonic development, we 
performed an integrative analysis of mRNA and miRNA cargo identified in oEVs [19] and the 
embryonic transcriptome alterations induced by oEVs observed in the present study. Meta-
enrichment functional analysis of these integrative data highlighted interesting functional terms 
highly enriched for the upregulated genes in embryos supplemented with frozen oEVs and the top 
500 oEV mRNAs dataset, such as “protein methylation” and “part of non-histone protein 
methylation”, which is a prevalent post-translational modification and important regulator of cellular 
signaling and function [62]. Functional terms enriched for downregulated genes in frozen oEV 
embryo treatment, predicted target genes of the miRNAs in oEVs, and the top 500 oEV mRNAs 
dataset were related to “reproductive structure development”, among others. The parent functional 
term “reproductive structure development” involves child terms such as “embryonic process 
involved in female pregnancy”, “in utero embryonic development”, “blastocyst development”, 
“stem cell population maintenance”, “in utero embryonic development”, “embryo development 
ending in birth or egg hatching”, “trophectodermal cell differentiation”, “decidualization”, 
“maternal placenta development”, and “epithelial cell differentiation involved in embryonic placenta 
development”. Moreover, our data showed that functional terms related to both gamete formation 
processes such as “oocyte maturation”, “polar body extrusion after meiotic divisions”, “spindle 
assembly involved in meiosis”, “spermatogenesis”, “binding of sperm to zona pellucida”, “sperm–
egg recognition regulation”, and “fertilization” were also enriched for downregulated genes in FoEV-
treated embryos, predicted target genes of miRNAs contained in oEVs, and the top 500 oEV mRNAs. 
Altogether, the biological processes and pathways mentioned above bring up potential functional 
roles of oEVs in modulating embryonic development and contributing to successful pregnancy. 
Therefore, based on the proprietary knowledge database of the IPA software, we focused the 
pathway analysis on the identification of genes in the list of FoEV treatment vs. Co DEGs associated 
with functions and processes related to embryonic development. The majority of the assigned genes 
were downregulated in embryos supplemented with frozen oEVs and were mainly related to 
apoptosis, proliferation, and viability of embryonic cells and cell lines in the IPA analysis. Many of 
these downregulated genes were assigned to enriched functional terms related to apoptosis, cell 
growth, proliferation, and embryonic morphogenesis in the Metascape analysis. One of the highly 
connected downregulated genes was NANOG, well-known as a pluripotency-sustaining factor in 
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embryonic stem cells [63]. In rabbits, lower NANOG expression has been found in in vivo embryos 
at the 16 cell, morula, and blastocyst stages compared to the same stages in in vitro produced embryos 
[64]. Since NANOG expression is restricted to the embryoblast (EB) and is repressed in trophectoderm 
(TE) cells [65], this lower expression in the total blastocyst could derive from a different ratio of the 
number of EB and TE cells at a given stage in in-vitro-produced and in vivo embryos. It was shown 
in a recent study [14] that culture of bovine embryos in the presence of BOEC-derived EVs increased 
the number of TE cells. Altogether, this could be an indication that supplementation of embryo 
culture with oEVs leads to a more in-vivo-like gene expression of Nanog. Sirtuin 1 (SIRT1) has been 
shown to regulate apoptosis and Nanog expression in embryonic stem cells in the mouse [66]. In our 
study, SIRT1 was downregulated in FoEV-treated embryos, which could have been due to miR-29b-
3p, which is found in bovine oEVs [19]. In mouse embryonic stem cells, Sirt1 has been identified as a 
direct target of miR-29b [67]. In addition to Sirt1, many more genes in the network were connected 
to the process “apoptosis of embryonic cell lines”. Some of the downregulated genes were typical 
apoptosis-promoting genes, such as APAF1, or genes that may have proapoptotic functions 
depending on the context, like TRIM32 [68], MAP3K1 [69], and ATF2 [70]. One of the downregulated 
and highly connected genes, MCL1, is actually described as an anti-apoptotic factor, but is expressed 
in different isoforms, whereas the short version of the MCL1 protein has a proapoptotic function 
[71,72]. For miR-10a, targeting APAF1 in the embryo-development-related network, anti-apoptotic 
effects have been shown after delivery by exosomes to follicular cells [73]. Interestingly, miR-101 has 
been shown recently to improve the early development of bovine somatic cell nuclear transfer 
embryos when overexpressed in the donor cells by increasing proliferation and vitality, and 
improving the early embryonic development [74]. 
Overall, the results revealed a network of genes and their regulatory miRNAs that suggested a 
mode of action of transferred oEV cargo inducing changes in embryonic gene expression which lead 
to a decrease in apoptosis of embryonic cells and improved embryo viability. For a variety of the 
identified miRNAs, a positive effect on embryonic development has been shown, for example miR-
23a-3p with increased expression in outgrowth embryos in the mouse [75], and miR-21-5p with 
positive effects on the development of murine embryos [76]. 
4. Materials and Methods 
Transcriptomic Analysis of Embryos by RNA Sequencing 
RNA Isolation, Low-Input Total RNA Library Preparation, and Sequencing 
In-vitro-produced bovine embryos cultured in the presence or absence of oEVs for 8 days were 
used for transcriptomic analysis by RNA sequencing in this study. The oEVs were obtained from the 
oviductal fluid of bovine oviducts collected from cows at a slaughterhouse, as described in detail in 
our previous studies [13,19]. According to the status of the ovary, the animals were determined to be 
in the postovulatory stage. Pools of 8–14 embryos cultured under three different treatments during 
in vitro embryo culture (IVC) were used for RNA isolation: (1) embryo samples supplemented with 
fresh oEVs (seven replicates, a total of 74 embryos in seven embryo pools); (2) embryo samples 
supplemented with frozen oEVs (eight replicates, a total of 81 embryos in eight embryo pools); and 
(3) embryo samples without supplementation (control) (six replicates, a total of 68 embryos in six 
embryo pools). Total RNA from these 21 embryo pool samples was isolated using the RNeasy Micro 
kit (QIAGEN AG, Hombrechtikon, Switzerland) according to the manufacturer’s instructions. RNA 
quality and concentration were analyzed using the Agilent Bioanalyzer 2100 (Agilent Technologies 
(Schweiz) AG, Basel, Switzerland), NanoDrop (Thermo Fisher Scientific (Schweiz) AG, Basel, 
Switzerland) and Quantus Quantiflour® RNA system (Promega AG, Dübendorf, Switzerland). 
Samples with best RNA quality and concentration were selected for the generation of RNA-seq 
libraries (15 libraries, five replicates/embryo treatments). For all samples, the RNA integrity number 
(RIN) was between 9 and 10. 
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For library preparation, the Ovation SOLO RNA-Seq System Kit (NuGEN Technologies, Inc. For 
Europe (Leek, The Netherlands) was used. Library preparation was done following the 
manufacturer’s instructions. In brief, aliquots of 1ng of total RNA were prepared for each embryo 
sample as starting material for RNA-seq library preparation. First, samples were subjected to DNase 
treatment and primer annealing, followed by cDNA processing and second-strand synthesis. After 
end repair, adapters were ligated and the first step of library amplification was performed by qPCR. 
To remove fragments derived from ribosomal RNAs, NuGEN’s insert-dependent adaptor cleavage 
(InDA-C) technology was applied in the next step. At the same time, strand selection was performed. 
After this step, the second library amplification and purification were performed for each sample 
using a universal primer and a set of barcode primers for sample multiplexing. Once RNA-seq 
libraries were prepared, quantitative and qualitative analyses were performed for each of the libraries 
using Agilent Bioanalyzer 2100 DNA High Sensitivity assays and Quantus Quantiflour® ONE 
dsDNA system (Promega). Sequencing of the libraries was done on an Illumina HiSeq 2500 
instrument (Illumina Inc., San Diego, CA, USA) at the Functional Genomics Center Zurich (FGCZ). 
Pooled barcoded libraries were run on two lanes of a single-end flow cell, generating between 4 and 
11 million single-end reads (125 bp) per sample. 
RNA-Sequencing Data Analysis 
The obtained sequence reads (Fastq files) were analyzed with an established analysis pipeline 
integrated in a local Galaxy installation [77] at the Animal Physiology group, ETH, Zurich. 
Processing, quality control, mapping, and quantification of the obtained sequences was performed 
as previously described [78]. The bovine genome assembly ARS-UCD1.2 (bosTau9) was used along 
with the corresponding GFF3 annotation file from NCBI. Based on mapping information for the reads 
(BAM files), a read count table for all annotated bovine genes was generated using QuasR Qcount. 
This count table was filtered to remove sequences with negligible read counts by using the counts 
per million (CPM) per sample filtering tool [79]. The mean library size and potential CPM cutoff 
(Counttable statistics, custom Galaxy tool) were calculated and the cutoff set to 4.21 CPM 
(corresponding to an average of 20 reads per library) for at least 3 out of 20 libraries. This count table 
was the basis for the subsequent statistical analysis. 
The analysis of differential gene expression was performed using BioConductor package EdgeR 
[80]. Data normalization was performed based on library size (TMM normalization) [81] and with the 
GLM robust (estimateGLMRobustDisp) [82] function. For comparison of the experimental groups, 
the following contrasts were set: Frozen versus Fresh, Frozen vs. Control, and Fresh vs. Control. An 
adjusted p-value (false discovery rate, FDR) of 0.05% was used as the threshold for significance of 
differentially expressed genes for the Frozen vs. Control comparison. Because of the much lower 
number of differentially expressed genes (DEGs) obtained for the other two comparisons, the 
likelihood ratio (LR) of 10.81 corresponding to FDR 0.05% in the Frozen vs. Fresh comparison was 
used as a threshold for the other two comparisons to achieve a comparable stringency and sensitivity 
of the significance analysis [83]. RNA-seq data were deposited in NCBI’s Gene Expression Omnibus 
and are accessible through GEO Series (GSE143596, 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143596). 
Data Mining and Bioinformatics Analysis 
Gene symbols and Entrez Gene IDs (bovine and putative human orthologs) were mapped for all 
transcripts using bioinformatics custom tools integrated in a local Galaxy installation. Custom 
database tools (NCBI annotation mapper, Mammalian Ortholog and Annotation database, MOADb 
[84]) were used to assign known or putative human orthologous genes. Human gene identifiers or 
symbols were used for subsequent functional annotation. 
To compare mRNAs altered in the presence of oEVs to oEV-derived mRNAs and potential genes 
targeted by miRNA-derived oEVs, Jvenn, an integrative tool for comparing lists of genes with Venn 
diagrams, was used [85]. Furthermore, statistical comparison of genes altered due to oEV treatment 
and mRNA and ncRNAs contained in oEVs was performed using GSEA software [86]. For GSEA, all 
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identified genes in embryos were ranked based on log2-fold change and FDR (log2(fold change + 2) 
× −log10(FDR)) [87]. The resulting preranked gene list containing the most significantly upregulated 
genes at the top of the list and the most significantly downregulated genes at the bottom was 
compared with mRNAs and ncRNAs derived from the oEV datasets [19]. To obtain information 
about overrepresented biological functions and pathways for the gene sets altered due to the oEV 
treatments and for further comprehensive comparison with oEV-derived RNAs, the Metascape tool 
was used [88]. QIAGEN Ingenuity Pathway Analysis software, Winter 2019 release 2019.4 (QIAGEN 
Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis, [89]) was also 
used for functional analysis, integration, and to understand embryonic gene expression data. 
MIENTURNET, an interactive web tool for microRNA target enrichment analysis based on 
miRTarBase (an up-to-date tool for validated interactions) and TargetScan (an up-to-date tool for 
sequence-based miRNA target predictions) was used [90]. To identify potential transcription factors 
regulating embryonic gene expression, ChEA3 was used [22]. 
5. Conclusions 
This study revealed a broad impact of oEVs on the embryo by providing the first high-
throughput analysis of the embryonic transcriptome regulated by oEVs. Our results showed a 
complex embryonic molecular signature modulated by oEVs, wherein the effects of oEVs are in fact 
the sum of multiple effects induced by the wide range of RNA components of oEVs (mRNAs, 
miRNAS, SNORDs, mRNAs encoding transcription factors). By integrating data from these different 
oEV components and their potential effects on the embryonic transcriptome, we proposed different 
modes of action of oEVs on the embryo. Our study provides the basis for in-depth functional 
investigations of the role of specific oEV RNA cargoes (mRNAs and miRNAs) controlling early 
embryonic development, which could impact embryo–maternal interactions and thus have key 
implications for reproductive success. 
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/xxx/s1. Supplementary 
Data S1. Transcriptomic data of embryos under different oEV treatments versus controls and data derived from 
integrative analysis with oEVs. Contains: Table S1. All identified transcripts in all embryos examined under 
different in vitro culture treatments. Table S2. Differentially expressed genes (DEGs) in embryos for the FoEV 
treatment vs. Co comparison. Table S3. Differentially expressed genes (DEGs) in embryos for the FeEV treatment 
vs. Co comparison. Table S4. Differentially expressed genes (DEGs) in embryos for the FoEV vs. FeEV treatment 
comparison. Table S5. Upregulated genes in FoEV-treated vs. Co embryos. Table S6. Downregulated genes in 
FoEV-treated vs. Co embryos. Table S7. All mRNAs identified in oEVs. Table S8. Top 500 most abundant mRNAs 
in oEVs. Table S9. Data derived from Venn diagram comparisons in Figure 5. Table S10. Data used for GSEA 
analysis in Figure 5. Table S11. Data derived from GSEA analysis for the Top 500 mRNAs in oEVs in Figure 5. 
Table S12. Data derived from GSEA analysis for the ncRNAs in oEVs in Figure 5. Table S13. Transcription factor 
analysis by ChEA3. Table S14. Data derived from Venn diagram comparisons in Figure 6. Table S15. Data used 
for Metascape circular comparisons. Supplementary Data S2. Functional analysis (FA) of transcripts up- or 
downregulated in embryos under different oEV treatments compared to control. Contains: Table S1. FA of 
transcripts downregulated in FoEV-treated embryos versus control. Table S2. FA of transcripts upregulated in 
FoEV-treated embryos versus control. Table S3. FA of transcripts downregulated in FeEV-treated embryos 
versus control. Table S4. FA of transcripts upregulated in FeEV-treated embryos versus control. Table S5. FA of 
transcripts downregulated in FoEV-treated versus FeEV-treated embryos. Table S6. FA of transcripts 
upregulated in FoEV-treated versus FeEV-treated embryos. Table S7 and Table S8. FA of transcripts included in 
Metascape circular analysis. Table S9 and Table S10. Molecules and pathways derived from IPA analysis and 
interaction pathways. 
Author Contributions: Conceptualization, S.B, P.M and C.A; formal analysis, S.B and C.A; funding acquisition, 
P.M and C.A; Investigation, S.B, P.M and C.A; supervision, C.A; writing—original draft preparation, S.B and 
C.A; writing—review and editing, S.B and C.A; All authors have read and agreed to the published version of 
the manuscript. 
Funding: This research was funded by INRA-CI_PHASE founds and the SNSF grant 31003A_173171 and EU in 
the framework of H2020-SFS-2015-2 under grant agreement n°677353-2 IMAGE. This work was also supported 
by COST-Action EPICONCEPT-FA1201 and COST-Action SLAAM- BM1308. 
Int. J. Mol. Sci. 2020, 21, 1303 24 of 28 
 
Acknowledgments: We would like to thank Susanne E. Ulbrich (ETH Zurich, Animal Physiology) for kindly 
allowing us to use her labs to prepare the RNA-seq libraries, Shuqin Zeng for helping with isolation of RNA, 
and the Functional Genomics Center Zurich (FGCZ) for performing Illumina sequencing. 
Conflicts of Interest: The authors declare no conflict of interest. 
Abbreviations 
EVs Extracellular vesicles 
oEVs Oviductal extracellular vesicles 
FeEVs Fresh oEVs 
FoEVs Frozen oEVs 
DEGs Differentially expressed genes 
IVC In vitro embryo culture 
References 
1. Maas, S.L.N.; Breakefield, X.O.; Weaver, A.M. Extracellular Vesicles: Unique Intercellular Delivery 
Vehicles. Trends Cell Biol. 2017, 27, 172–188, doi:10.1016/j.tcb.2016.11.003. 
2. Simons, M.; Raposo, G. Exosomes—Vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 
2009, 21, 575–581, doi:10.1016/j.ceb.2009.03.007. 
3. Raposo, G.; Stoorvogel, W. Extracellular vesicles: Exosomes, microvesicles, and friends. J. Cell Biol. 2013, 
200, 373–383, doi:10.1083/jcb.201211138. 
4. van der Pol, E.; Boing, A.N.; Harrison, P.; Sturk, A.; Nieuwland, R. Classification, functions, and clinical 
relevance of extracellular vesicles. Pharmacol. Rev. 2012, 64, 676–705, doi:10.1124/pr.112.005983. 
5. Yanez-Mo, M.; Siljander, P.R.; Andreu, Z.; Zavec, A.B.; Borras, F.E.; Buzas, E.I.; Buzas, K.; Casal, E.; 
Cappello, F.; Carvalho, J.; et al. Biological properties of extracellular vesicles and their physiological 
functions. J. Extracell. Vesicles 2015, 4, 27066, doi:10.3402/jev.v4.27066. 
6. Gyorgy, B.; Szabo, T.G.; Pasztoi, M.; Pal, Z.; Misjak, P.; Aradi, B.; Laszlo, V.; Pallinger, E.; Pap, E.; Kittel, A.; 
et al. Membrane vesicles, current state-of-the-art: Emerging role of extracellular vesicles. Cell. Mol. Life Sci. 
2011, 68, 2667–2688, doi:10.1007/s00018-011-0689-3. 
7. Tannetta, D.; Dragovic, R.; Alyahyaei, Z.; Southcombe, J. Extracellular vesicles and reproduction-
promotion of successful pregnancy. Cell. Mol. Immunol. 2014, 11, 548–563, doi:10.1038/cmi.2014.42. 
8. Barkalina, N.; Jones, C.; Wood, M.J.; Coward, K. Extracellular vesicle-mediated delivery of molecular 
compounds into gametes and embryos: Learning from nature. Hum. Reprod. Update 2015, 21, 627–639, 
doi:10.1093/humupd/dmv027. 
9. Saadeldin, I.M.; Oh, H.J.; Lee, B.C. Embryonic-maternal cross-talk via exosomes: Potential implications. 
Stem Cells Cloning Adv. Appl. 2015, 8, 103–107, doi:10.2147/SCCAA.S84991. 
10. Ng, Y.H.; Rome, S.; Jalabert, A.; Forterre, A.; Singh, H.; Hincks, C.L.; Salamonsen, L.A. Endometrial 
exosomes/microvesicles in the uterine microenvironment: A new paradigm for embryo-endometrial cross 
talk at implantation. PLoS ONE 2013, 8, e58502, doi:10.1371/journal.pone.0058502. 
11. Al-Dossary, A.A.; Strehler, E.E.; Martin-Deleon, P.A. Expression and secretion of plasma membrane Ca2+-
ATPase 4a (PMCA4a) during murine estrus: Association with oviductal exosomes and uptake in sperm. 
PLoS ONE 2013, 8, e80181, doi:10.1371/journal.pone.0080181. 
12. Alminana, C.; Bauersachs, S. Extracellular Vesicles in the Oviduct: Progress, Challenges and Implications 
for the Reproductive Success. Bioengineering 2019, 6, 32, doi:10.3390/bioengineering6020032. 
13. Alminana, C.; Corbin, E.; Tsikis, G.; Alcantara-Neto, A.S.; Labas, V.; Reynaud, K.; Galio, L.; Uzbekov, R.; 
Garanina, A.S.; Druart, X.; et al. Oviduct extracellular vesicles protein content and their role during oviduct-
embryo cross-talk. Reproduction 2017, 154, 153–168, doi:10.1530/REP-17-0054. 
14. Lopera-Vasquez, R.; Hamdi, M.; Fernandez-Fuertes, B.; Maillo, V.; Beltran-Brena, P.; Calle, A.; Redruello, 
A.; Lopez-Martin, S.; Gutierrez-Adan, A.; Yanez-Mo, M.; et al. Extracellular Vesicles from BOEC in In Vitro 
Embryo Development and Quality. PLoS ONE 2016, 11, e0148083, doi:10.1371/journal.pone.0148083. 
15. Lange-Consiglio, A.; Perrini, C.; Albini, G.; Modina, S.; Lodde, V.; Orsini, E.; Esposti, P.; Cremonesi, F. 
Oviductal microvesicles and their effect on in vitro maturation of canine oocytes. Reproduction 2017, 154, 
167–180, doi:10.1530/REP-17-0117. 
Int. J. Mol. Sci. 2020, 21, 1303 25 of 28 
 
16. Ferraz, M.; Carothers, A.; Dahal, R.; Noonan, M.J.; Songsasen, N. Oviductal extracellular vesicles interact 
with the spermatozoon’s head and mid-piece and improves its motility and fertilizing ability in the 
domestic cat. Sci. Rep. 2019, 9, 9484, doi:10.1038/s41598-019-45857-x. 
17. Alcantara-Neto, A.S.; Fernandez-Rufete, M.; Corbin, E.; Tsikis, G.; Uzbekov, R.; Garanina, A.S.; Coy, P.; 
Alminana, C.; Mermillod, P. Oviduct fluid extracellular vesicles regulate polyspermy during porcine 
invitro fertilisation. Reprod. Fertil. Dev. 2019, doi:10.1071/RD19058. 
18. Lopera-Vasquez, R.; Hamdi, M.; Maillo, V.; Gutierrez-Adan, A.; Bermejo-Alvarez, P.; Ramirez, M.A.; 
Yanez-Mo, M.; Rizos, D. Effect of bovine oviductal extracellular vesicles on embryo development and 
quality in vitro. Reprod. Fertil. Dev. 2017, 153, 461–470, doi:10.1530/REP-16-0384. 
19. Alminana, C.; Tsikis, G.; Labas, V.; Uzbekov, R.; da Silveira, J.C.; Bauersachs, S.; Mermillod, P. Deciphering 
the oviductal extracellular vesicles content across the estrous cycle: Implications for the gametes-oviduct 
interactions and the environment of the potential embryo. BMC Genom. 2018, 19, 622, doi:10.1186/s12864-
018-4982-5. 
20. Gatien, J.; Mermillod, P.; Tsikis, G.; Bernardi, O.; Janati Idrissi, S.; Uzbekov, R.; Le Bourhis, D.; Salvetti, P.; 
Alminana, C.; Saint-Dizier, M. Metabolomic Profile of Oviductal Extracellular Vesicles across the Estrous 
Cycle in Cattle. Int. J. Mol. Sci. 2019, 20, 6339, doi:10.3390/ijms20246339. 
21. Subramanian, A.; Kuehn, H.; Gould, J.; Tamayo, P.; Mesirov, J.P. GSEA-P: A desktop application for Gene 
Set Enrichment Analysis. Bioinformatics 2007, 23, 3251–3253, doi:10.1093/bioinformatics/btm369. 
22. Keenan, A.B.; Torre, D.; Lachmann, A.; Leong, A.K.; Wojciechowicz, M.L.; Utti, V.; Jagodnik, K.M.; 
Kropiwnicki, E.; Wang, Z.; Ma’ayan, A. ChEA3: Transcription factor enrichment analysis by orthogonal 
omics integration. Nucleic Acids Res. 2019, 47, 212–224, doi:10.1093/nar/gkz446. 
23. Sokolova, V.; Ludwig, A.K.; Hornung, S.; Rotan, O.; Horn, P.A.; Epple, M.; Giebel, B. Characterisation of 
exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. 
Colloids Surf. B Biointerfaces 2011, 87, 146–150, doi:10.1016/j.colsurfb.2011.05.013. 
24. Sarker, S.; Scholz-Romero, K.; Perez, A.; Illanes, S.E.; Mitchell, M.D.; Rice, G.E.; Salomon, C. Placenta-
derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. J. 
Transl. Med. 2014, 12, 204, doi:10.1186/1479-5876-12-204. 
25. Bosch, S.; de Beaurepaire, L.; Allard, M.; Mosser, M.; Heichette, C.; Chretien, D.; Jegou, D.; Bach, J.M. 
Trehalose prevents aggregation of exosomes and cryodamage. Sci. Rep. 2016, 6, 36162, 
doi:10.1038/srep36162. 
26. Maroto, R.; Zhao, Y.; Jamaluddin, M.; Popov, V.L.; Wang, H.; Kalubowilage, M.; Zhang, Y.; Luisi, J.; Sun, 
H.; Culbertson, C.T.; et al. Effects of storage temperature on airway exosome integrity for diagnostic and 
functional analyses. J. Extracell. Vesicles 2017, 6, 1359478, doi:10.1080/20013078.2017.1359478. 
27. Teng, X.; Chen, L.; Chen, W.; Yang, J.; Yang, Z.; Shen, Z. Mesenchymal Stem Cell-Derived Exosomes 
Improve the Microenvironment of Infarcted Myocardium Contributing to Angiogenesis and Anti-
Inflammation. Cell. Physiol. Biochem. 2015, 37, 2415–2424, doi:10.1159/000438594. 
28. Zhou, H.; Yuen, P.S.; Pisitkun, T.; Gonzales, P.A.; Yasuda, H.; Dear, J.W.; Gross, P.; Knepper, M.A.; Star, 
R.A. Collection, storage, preservation, and normalization of human urinary exosomes for biomarker 
discovery. Kidney Int. 2006, 69, 1471–1476, doi:10.1038/sj.ki.5000273. 
29. Jayachandran, M.; Miller, V.M.; Heit, J.A.; Owen, W.G. Methodology for isolation, identification and 
characterization of microvesicles in peripheral blood. J. Immunol. Methods 2012, 375, 207–214, 
doi:10.1016/j.jim.2011.10.012. 
30. Holm, P.; Booth, P.J.; Schmidt, M.H.; Greve, T.; Callesen, H. High bovine blastocyst development in a static 
in vitro production system using SOFaa medium supplemented with sodium citrate and myo-inositol with 
or without serum-proteins. Theriogenology 1999, 52, 683–700, doi:10.1016/S0093-691X(99)00162-4. 
31. da Silveira, J.C.; Andrade, G.M.; Del Collado, M.; Sampaio, R.V.; Sangalli, J.R.; Silva, L.A.; Pinaffi, F.V.L.; 
Jardim, I.B.; Cesar, M.C.; Nogueira, M.F.G.; et al. Supplementation with small-extracellular vesicles from 
ovarian follicular fluid during in vitro production modulates bovine embryo development. PLoS ONE 2017, 
12, e0179451, doi:10.1371/journal.pone.0179451. 
32. Gross, N.; Kropp, J.; Khatib, H. MicroRNA Signaling in Embryo Development. Biology 2017, 6, 34, 
doi:10.3390/biology6030034. 
33. Liang, J.; Wang, S.; Wang, Z. Role of microRNAs in embryo implantation. Reprod. Biol. Endocrinol. 2017, 15, 
90, doi:10.1186/s12958-017-0309-7. 
Int. J. Mol. Sci. 2020, 21, 1303 26 of 28 
 
34. Matera, A.G.; Terns, R.M.; Terns, M.P. Non-coding RNAs: Lessons from the small nuclear and small 
nucleolar RNAs. Nat. Rev. Mol. Cell Biol. 2007, 8, 209–220, doi:10.1038/nrm2124. 
35. Bratkovic, T.; Rogelj, B. Biology and applications of small nucleolar RNAs. Cell. Mol. Life Sci. 2011, 68, 3843–
3851, doi:10.1007/s00018-011-0762-y. 
36. Ravo, M.; Cordella, A.; Rinaldi, A.; Bruno, G.; Alexandrova, E.; Saggese, P.; Nassa, G.; Giurato, G.; Tarallo, 
R.; Marchese, G.; et al. Small non-coding RNA deregulation in endometrial carcinogenesis. Oncotarget 2015, 
6, 4677–4691, doi:10.18632/oncotarget.2911. 
37. Liao, J.; Yu, L.; Mei, Y.; Guarnera, M.; Shen, J.; Li, R.; Liu, Z.; Jiang, F. Small nucleolar RNA signatures as 
biomarkers for non-small-cell lung cancer. Mol. Cancer 2010, 9, 198, doi:10.1186/1476-4598-9-198. 
38. El Hajj, N.; Haertle, L.; Dittrich, M.; Denk, S.; Lehnen, H.; Hahn, T.; Schorsch, M.; Haaf, T. DNA methylation 
signatures in cord blood of ICSI children. Hum. Reprod. 2017, 32, 1761–1769, doi:10.1093/humrep/dex209. 
39. Mellisho, E.A.; Briones, M.A.; Velasquez, A.E.; Cabezas, J.; Castro, F.O.; Rodriguez-Alvarez, L. Extracellular 
vesicles secreted during blastulation show viability of bovine embryos. Reproduction 2019, 158, 477–492, 
doi:10.1530/REP-19-0233. 
40. Lu, W.; Yu, J.; Shi, F.; Zhang, J.; Huang, R.; Yin, S.; Songyang, Z.; Huang, J. The long non-coding RNA Snhg3 
is essential for mouse embryonic stem cell self-renewal and pluripotency. Stem Cell Res. Ther. 2019, 10, 157, 
doi:10.1186/s13287-019-1270-5. 
41. Cuthbert, J.M.; Russell, S.J.; White, K.L.; Benninghoff, A.D. The maternal-to-zygotic transition in bovine in 
vitro-fertilized embryos is associated with marked changes in small non-coding RNAsdagger. Biol. Reprod. 
2019, 100, 331–350, doi:10.1093/biolre/ioy190. 
42. Bland, C.L.; Byrne-Hoffman, C.N.; Fernandez, A.; Rellick, S.L.; Deng, W.; Klinke, D.J., II. Exosomes derived 
from B16F0 melanoma cells alter the transcriptome of cytotoxic T cells that impacts mitochondrial 
respiration. FEBS J. 2018, 285, 1033–1050, doi:10.1111/febs.14396. 
43. Mitchell, K.J.; Pinson, K.I.; Kelly, O.G.; Brennan, J.; Zupicich, J.; Scherz, P.; Leighton, P.A.; Goodrich, L.V.; 
Lu, X.; Avery, B.J.; et al. Functional analysis of secreted and transmembrane proteins critical to mouse 
development. Nat. Genet. 2001, 28, 241–249, doi:10.1038/90074. 
44. Suresh, P.S.; Tsutsumi, R.; Venkatesh, T. YBX1 at the crossroads of non-coding transcriptome, exosomal, 
and cytoplasmic granular signaling. Eur. J. Cell Biol. 2018, 97, 163–167, doi:10.1016/j.ejcb.2018.02.003. 
45. Eliseeva, I.A.; Kim, E.R.; Guryanov, S.G.; Ovchinnikov, L.P.; Lyabin, D.N. Y-box-binding protein 1 (YB-1) 
and its functions. Biochemistry 2011, 76, 1402–1433, doi:10.1134/S0006297911130049. 
46. Shurtleff, M.J.; Yao, J.; Qin, Y.; Nottingham, R.M.; Temoche-Diaz, M.M.; Schekman, R.; Lambowitz, A.M. 
Broad role for YBX1 in defining the small noncoding RNA composition of exosomes. Proc. Natl. Acad. Sci. 
USA 2017, 114, 8987–8995, doi:10.1073/pnas.1712108114. 
47. Kossinova, O.A.; Gopanenko, A.V.; Tamkovich, S.N.; Krasheninina, O.A.; Tupikin, A.E.; Kiseleva, E.; 
Yanshina, D.D.; Malygin, A.A.; Ven’yaminova, A.G.; Kabilov, M.R.; et al. Cytosolic YB-1 and NSUN2 are 
the only proteins recognizing specific motifs present in mRNAs enriched in exosomes. Biochim. Biophys. 
Acta Proteins Proteom. 2017, 1865, 664–673, doi:10.1016/j.bbapap.2017.03.010. 
48. Yang, Y.; Wang, L.; Han, X.; Yang, W.L.; Zhang, M.; Ma, H.L.; Sun, B.F.; Li, A.; Xia, J.; Chen, J.; et al. RNA 
5-Methylcytosine Facilitates the Maternal-to-Zygotic Transition by Preventing Maternal mRNA Decay. 
Mol. Cell 2019, 75, 1188–1202, doi:10.1016/j.molcel.2019.06.033. 
49. Leyens, G.; Knoops, B.; Donnay, I. Expression of peroxiredoxins in bovine oocytes and embryos produced 
in vitro. Mol. Reprod. Dev. 2004, 69, 243–251, doi:10.1002/mrd.20145. 
50. Lee, M.S.; Liu, C.H.; Lee, T.H.; Wu, H.M.; Huang, C.C.; Huang, L.S.; Chen, C.M.; Cheng, E.H. Association 
of creatin kinase B and peroxiredoxin 2 expression with age and embryo quality in cumulus cells. J. Assist. 
Reprod. Genet. 2010, 27, 629–639, doi:10.1007/s10815-010-9459-7. 
51. Wu, F.; Tian, F.; Zeng, W.; Liu, X.; Fan, J.; Lin, Y.; Zhang, Y. Role of peroxiredoxin2 downregulation in 
recurrent miscarriage through regulation of trophoblast proliferation and apoptosis. Cell Death Dis. 2017, 
8, e2908, doi:10.1038/cddis.2017.301. 
52. Nakagawa, S.; Shimada, M.; Yanaka, K.; Mito, M.; Arai, T.; Takahashi, E.; Fujita, Y.; Fujimori, T.; Standaert, 
L.; Marine, J.C.; et al. The lncRNA Neat1 is required for corpus luteum formation and the establishment of 
pregnancy in a subpopulation of mice. Development 2014, 141, 4618–4627, doi:10.1242/dev.110544. 
53. Hamazaki, J.; Sasaki, K.; Kawahara, H.; Hisanaga, S.; Tanaka, K.; Murata, S. Rpn10-mediated degradation 
of ubiquitinated proteins is essential for mouse development. Mol. Cell. Biol. 2007, 27, 6629–6638, 
doi:10.1128/MCB.00509-07. 
Int. J. Mol. Sci. 2020, 21, 1303 27 of 28 
 
54. Xuan, B.; Li, Z.C.; Wang, Q.Y.; Xu, M.; Chen, X.; Jin, Y. Inhibition of PSMD4 alters ZP1 ubiquitination state 
and sperm-oocyte-binding ability in pigs. Reprod. Domest. Anim. 2018, 53, 688–694, doi:10.1111/rda.13158. 
55. Zhao, C.; Meng, A. Sp1-like transcription factors are regulators of embryonic development in vertebrates. 
Dev. Growth Differ. 2005, 47, 201–211, doi:10.1111/j.1440-169X.2005.00797.x. 
56. Bouwman, P.; Gollner, H.; Elsasser, H.P.; Eckhoff, G.; Karis, A.; Grosveld, F.; Philipsen, S.; Suske, G. 
Transcription factor Sp3 is essential for post-natal survival and late tooth development. EMBO J. 2000, 19, 
655–661, doi:10.1093/emboj/19.4.655. 
57. Akira, S.; Takeda, K.; Kaisho, T. Toll-like receptors: Critical proteins linking innate and acquired immunity. 
Nat. Immunol. 2001, 2, 675–680, doi:10.1038/90609. 
58. Koga, K.; Aldo, P.B.; Mor, G. Toll-like receptors and pregnancy: Trophoblast as modulators of the immune 
response. J. Obstet. Gynaecol. Res. 2009, 35, 191–202, doi:10.1111/j.1447-0756.2008.00963.x. 
59. Lehmann, S.M.; Kruger, C.; Park, B.; Derkow, K.; Rosenberger, K.; Baumgart, J.; Trimbuch, T.; Eom, G.; 
Hinz, M.; Kaul, D.; et al. An unconventional role for miRNA: Let-7 activates Toll-like receptor 7 and causes 
neurodegeneration. Nat. Neurosci. 2012, 15, 827–835, doi:10.1038/nn.3113. 
60. Fabbri, M.; Paone, A.; Calore, F.; Galli, R.; Gaudio, E.; Santhanam, R.; Lovat, F.; Fadda, P.; Mao, C.; Nuovo, 
G.J.; et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. 
Acad. Sci. USA 2012, 109, 2110–2116, doi:10.1073/pnas.1209414109. 
61. Xie, M.Y.; Hou, L.J.; Sun, J.J.; Zeng, B.; Xi, Q.Y.; Luo, J.Y.; Chen, T.; Zhang, Y.L. Porcine Milk Exosome 
MiRNAs Attenuate LPS-Induced Apoptosis through Inhibiting TLR4/NF-kappaB and p53 Pathways in 
Intestinal Epithelial Cells. J. Agric. Food Chem. 2019, 67, 9477–9491, doi:10.1021/acs.jafc.9b02925. 
62. Biggar, K.K.; Li, S.S. Non-histone protein methylation as a regulator of cellular signalling and function. Nat. 
Rev. Mol. Cell Biol. 2015, 16, 5–17, doi:10.1038/nrm3915. 
63. Chambers, I.; Colby, D.; Robertson, M.; Nichols, J.; Lee, S.; Tweedie, S.; Smith, A. Functional expression 
cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003, 113, 643–655, 
doi:10.1016/s0092-8674(03)00392-1. 
64. Henderson, G.R.; Brahmasani, S.R.; Yelisetti, U.M.; Konijeti, S.; Katari, V.C.; Sisinthy, S. Candidate gene 
expression patterns in rabbit preimplantation embryos developed in vivo and in vitro. J. Assist. Reprod. 
Genet. 2014, 31, 899–911, doi:10.1007/s10815-014-0233-0. 
65. Kuckenberg, P.; Buhl, S.; Woynecki, T.; van Furden, B.; Tolkunova, E.; Seiffe, F.; Moser, M.; Tomilin, A.; 
Winterhager, E.; Schorle, H. The transcription factor TCFAP2C/AP-2gamma cooperates with CDX2 to 
maintain trophectoderm formation. Mol. Cell. Biol. 2010, 30, 3310–3320, doi:10.1128/MCB.01215-09. 
66. Han, M.K.; Song, E.K.; Guo, Y.; Ou, X.; Mantel, C.; Broxmeyer, H.E. SIRT1 regulates apoptosis and Nanog 
expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell 2008, 
2, 241–251, doi:10.1016/j.stem.2008.01.002. 
67. Xu, Z.; Zhang, L.; Fei, X.; Yi, X.; Li, W.; Wang, Q. The miR-29b-Sirt1 axis regulates self-renewal of mouse 
embryonic stem cells in response to reactive oxygen species. Cell Signal. 2014, 26, 1500–1505, 
doi:10.1016/j.cellsig.2014.03.010. 
68. Ryu, Y.S.; Lee, Y.; Lee, K.W.; Hwang, C.Y.; Maeng, J.S.; Kim, J.H.; Seo, Y.S.; You, K.H.; Song, B.; Kwon, K.S. 
TRIM32 protein sensitizes cells to tumor necrosis factor (TNFalpha)-induced apoptosis via its RING 
domain-dependent E3 ligase activity against X-linked inhibitor of apoptosis (XIAP). J. Biol. Chem. 2011, 286, 
25729–25738, doi:10.1074/jbc.M111.241893. 
69. Suddason, T.; Gallagher, E. A RING to rule them all? Insights into the Map3k1 PHD motif provide a new 
mechanistic understanding into the diverse roles of Map3k1. Cell Death Differ. 2015, 22, 540–548, 
doi:10.1038/cdd.2014.239. 
70. Vlahopoulos, S.A.; Logotheti, S.; Mikas, D.; Giarika, A.; Gorgoulis, V.; Zoumpourlis, V. The role of ATF-2 
in oncogenesis. Bioessays 2008, 30, 314–327, doi:10.1002/bies.20734. 
71. Kim, J.H.; Sim, S.H.; Ha, H.J.; Ko, J.J.; Lee, K.; Bae, J. MCL-1ES, a novel variant of MCL-1, associates with 
MCL-1L and induces mitochondrial cell death. FEBS Lett. 2009, 583, 2758–2764, 
doi:10.1016/j.febslet.2009.08.006. 
72. Bae, J.; Leo, C.P.; Hsu, S.Y.; Hsueh, A.J. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family 
member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J. Biol. Chem. 2000, 275, 
25255–25261, doi:10.1074/jbc.M909826199. 
Int. J. Mol. Sci. 2020, 21, 1303 28 of 28 
 
73. Xiao, G.Y.; Cheng, C.C.; Chiang, Y.S.; Cheng, W.T.; Liu, I.H.; Wu, S.C. Exosomal miR-10a derived from 
amniotic fluid stem cells preserves ovarian follicles after chemotherapy. Sci. Rep. 2016, 6, 23120, 
doi:10.1038/srep23120. 
74. Chang, H.Y.; Xie, R.X.; Zhang, L.; Fu, L.Z.; Zhang, C.T.; Chen, H.H.; Wang, Z.Q.; Zhang, Y.; Quan, F.S. 
Overexpression of miR-101-2 in donor cells improves the early development of Holstein cow somatic cell 
nuclear transfer embryos. J. Dairy Sci. 2019, 102, 4662–4673, doi:10.3168/jds.2018-15072. 
75. Kim, J.; Lee, J.; Jun, J.H. Identification of differentially expressed microRNAs in outgrowth embryos 
compared with blastocysts and non-outgrowth embryos in mice. Reprod. Fertil. Dev. 2019, 31, 645–657, 
doi:10.1071/RD18161. 
76. Lv, C.; Yu, W.X.; Wang, Y.; Yi, D.J.; Zeng, M.H.; Xiao, H.M. MiR-21 in extracellular vesicles contributes to 
the growth of fertilized eggs and embryo development in mice. Biosci. Rep. 2018, 38, 
doi:10.1042/BSR20180036. 
77. Giardine, B.; Riemer, C.; Hardison, R.C.; Burhans, R.; Elnitski, L.; Shah, P.; Zhang, Y.; Blankenberg, D.; 
Albert, I.; Taylor, J.; et al. Galaxy: A platform for interactive large-scale genome analysis. Genome Res. 2005, 
15, 1451–1455, doi:10.1101/gr.4086505. 
78. Zeng, S.; Ulbrich, S.E.; Bauersachs, S. Spatial organization of endometrial gene expression at the onset of 
embryo attachment in pigs. BMC Genom. 2019, 20, 895, doi:10.1186/s12864-019-6264-2. 
79. Chen, Y.; Mccarthy, D.; Robinson, M.; Smyth, G.K. edgeR: Differential Expression Analysis of Digital Gene 
Expression Data User’s Guide. 2017 Available online: 
www.bioconductor.org/packages/release/bioc/vignettes/edgeR/inst/doc/edgeRUsersGuide.pdf (accessed 
on 12 February 2020) 
80. Robinson, M.D.; McCarthy, D.J.; Smyth, G.K. edgeR: A Bioconductor package for differential expression 
analysis of digital gene expression data. Bioinformatics 2010, 26, 139–140, doi:10.1093/bioinformatics/btp616. 
81. Robinson, M.D.; Oshlack, A. A scaling normalization method for differential expression analysis of RNA-
seq data. Genome Biol. 2010, 11, R25, doi:10.1186/gb-2010-11-3-r25. 
82. Zhou, X.; Lindsay, H.; Robinson, M.D. Robustly detecting differential expression in RNA sequencing data 
using observation weights. Nucleic Acids Res. 2014, 42, e91, doi:10.1093/nar/gku310. 
83. Hackstadt, A.J.; Hess, A.M. Filtering for increased power for microarray data analysis. BMC Bioinform. 2009, 
10, 11, doi:10.1186/1471-2105-10-11. 
84. Bick, J.T.; Zeng, S.; Robinson, M.D.; Ulbrich, S.E.; Bauersachs, S. Mammalian Annotation Database for 
improved annotation and functional classification of Omics datasets from less well-annotated organisms. 
Database 2019, 2019, doi:10.1093/database/baz086. 
85. Bardou, P.; Mariette, J.; Escudie, F.; Djemiel, C.; Klopp, C. jvenn: An interactive Venn diagram viewer. BMC 
Bioinform. 2014, 15, 293, doi:10.1186/1471-2105-15-293. 
86. Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; 
Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach 
for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550, 
doi:10.1073/pnas.0506580102. 
87. Merkl, M.; Ulbrich, S.E.; Otzdorff, C.; Herbach, N.; Wanke, R.; Wolf, E.; Handler, J.; Bauersachs, S. 
Microarray analysis of equine endometrium at days 8 and 12 of pregnancy. Biol. Reprod. 2010, 83, 874–886, 
doi:10.1095/biolreprod.110.085233. 
88. Zhou, Y.; Zhou, B.; Pache, L.; Chang, M.; Khodabakhshi, A.H.; Tanaseichuk, O.; Benner, C.; Chanda, S.K. 
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 
2019, 10, 1523, doi:10.1038/s41467-019-09234-6. 
89. Kramer, A.; Green, J.; Pollard, J., Jr.; Tugendreich, S. Causal analysis approaches in Ingenuity Pathway 
Analysis. Bioinformatics 2014, 30, 523–530, doi:10.1093/bioinformatics/btt703. 
90. Licursi, V.; Conte, F.; Fiscon, G.; Paci, P. MIENTURNET: An interactive web tool for microRNA-target 
enrichment and network-based analysis. BMC Bioinform. 2019, 20, 545, doi:10.1186/s12859-019-3105-x. 
 
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
